Research ArticleNeurology
Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology
Andreas Hahn, Martin Schain, Maria Erlandsson, Petter Sjölin, Gregory M. James, Olof T. Strandberg, Douglas Hägerström, Rupert Lanzenberger, Jonas Jögi, Tomas G. Olsson, Ruben Smith and Oskar Hansson
Journal of Nuclear Medicine April 2017, 58 (4) 623-631; DOI: https://doi.org/10.2967/jnumed.116.174508
Andreas Hahn
1Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
Martin Schain
2Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden
Maria Erlandsson
3Department of Radiation Physics, Skåne University Hospital, Lund, Sweden
Petter Sjölin
3Department of Radiation Physics, Skåne University Hospital, Lund, Sweden
Gregory M. James
1Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
Olof T. Strandberg
2Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden
Douglas Hägerström
4Department of Clinical Neurophysiology, Skåne University Hospital, Lund, Sweden
Rupert Lanzenberger
1Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
Jonas Jögi
5Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, Sweden
Tomas G. Olsson
3Department of Radiation Physics, Skåne University Hospital, Lund, Sweden
Ruben Smith
6Department of Neurology, Skåne University Hospital, Lund, Sweden; and
Oskar Hansson
2Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden
7Memory Clinic, Skåne University Hospital, Malmö, Sweden
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 58, Issue 4
April 1, 2017
Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology
Andreas Hahn, Martin Schain, Maria Erlandsson, Petter Sjölin, Gregory M. James, Olof T. Strandberg, Douglas Hägerström, Rupert Lanzenberger, Jonas Jögi, Tomas G. Olsson, Ruben Smith, Oskar Hansson
Journal of Nuclear Medicine Apr 2017, 58 (4) 623-631; DOI: 10.2967/jnumed.116.174508
Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology
Andreas Hahn, Martin Schain, Maria Erlandsson, Petter Sjölin, Gregory M. James, Olof T. Strandberg, Douglas Hägerström, Rupert Lanzenberger, Jonas Jögi, Tomas G. Olsson, Ruben Smith, Oskar Hansson
Journal of Nuclear Medicine Apr 2017, 58 (4) 623-631; DOI: 10.2967/jnumed.116.174508
Jump to section
Related Articles
Cited By...
- The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification
- Patient-centered connectivity-based prediction of tau pathology spread in Alzheimers disease
- Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimers disease
- The implications of different approaches to define AT(N) in Alzheimer disease
- Evaluation of 18F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain
- Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
- In vivo retention of 18F-AV-1451 in corticobasal syndrome